Faessen Janine P M, Oerlemans Dennis J A J, de Jong Marc R P A, Overbeek Jetty A, Vissers Pauline A J, Aben Katja K H, Janssen-Heijnen Maryska L G, van den Bergh Joop P W, van Osch Frits H M
Department of Clinical Epidemiology, VieCuri Medical Centre, Venlo, The Netherlands.
Department of Human Nutrition, Wageningen University & Research, Wageningen, The Netherlands.
Bladder Cancer. 2023 Mar 31;9(1):73-82. doi: 10.3233/BLC-220082. eCollection 2023.
Observational studies indicate a potential association between diabetes medication use and aggressiveness of bladder cancer.
The objective is to exploratively study the association between diabetes medication use, as proxy for diabetes, and cancer characteristics of urothelial carcinoma at diagnosis. Furthermore, differences in associations between specific types of diabetes medication are studied.
The association between use of diabetes medication and urothelial carcinoma (UC) characteristics at diagnosis is studied. A retrospective registry-based study among UC patients in the Netherlands was performed for which two large linked registries from PHARMO and IKNL were used. Patients diagnosed with UC between 2000 and 2016 and no previous cancer were included in this study. In this study, 1,168 UC patients who were diabetes medication users were included as well as 3,609 non-users. Conditional logistic regression analysis was performed to determine odds ratios comparing cancer characteristics between different types of diabetes medication users to non-users.
Noninsulin antidiabetic drugs (NIAD) use was associated with a muscle-invasive type of UC compared to non-users (OR = 1.31, 95% CI: 1.10-1.55 for T2+ versus Ta) as well as a poorly differentiated tumour (OR = 1.31, 95% CI: 1.07-1.59 for poorly versus well differentiated tumours).
Users of diabetes medication are potentially more likely to be diagnosed with a more aggressive tumour than non-users; however, lifestyle factors could not be adjusted for.
观察性研究表明糖尿病药物使用与膀胱癌侵袭性之间可能存在关联。
旨在探索性研究作为糖尿病替代指标的糖尿病药物使用与尿路上皮癌诊断时的癌症特征之间的关联。此外，还研究了特定类型糖尿病药物之间关联的差异。
研究糖尿病药物使用与尿路上皮癌（UC）诊断时特征之间的关联。在荷兰对UC患者进行了一项基于登记处的回顾性研究，使用了来自PHARMO和IKNL的两个大型关联登记处。纳入2000年至2016年间诊断为UC且既往无癌症的患者。本研究纳入了1168名使用糖尿病药物的UC患者以及3609名未使用者。进行条件逻辑回归分析以确定不同类型糖尿病药物使用者与未使用者之间癌症特征比较的比值比。
与未使用者相比，使用非胰岛素抗糖尿病药物（NIAD）与肌肉浸润型UC相关（T2 + 期与Ta期相比，OR = 1.31，95%CI：1.10 - 1.55），也与低分化肿瘤相关（低分化与高分化肿瘤相比，OR = 1.31，95%CI：1.07 - 1.59）。
糖尿病药物使用者比未使用者更有可能被诊断出患有侵袭性更强的肿瘤；然而，无法对生活方式因素进行调整。
